Vertaling van "programs for patients with malaria " (Nederlands → Frans) :

The foundation also runs access-to-treatment programs for patients with malaria and tuberculosis.
La Fondation gère également des programmes visant à faciliter l’accès aux soins pour des patients atteints de malaria ou de tuberculose.

Access-to-medicine programs including medication for malaria and leprosy reach 80 million patients in 2009 with contributions valued at USD 1.5 billion, or 3% of sales
Les programmes d’accès aux médicaments, qui comprennent des traitements contre le paludisme et la lèpre ont touché 80 millions de malades en 2009 avec des contributions s’élevant à USD 1,5 milliard soit 3% des ventes

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.

These programs have reduced the number of leprosy cases, with four million patients treated since 2000.
Il s’en est suivi une réduction des cas de lèpre, et quatre millions de malades ont été soignés depuis 2000.

Initial data from the Phase III program with over 4,200 patients in 30 countries suggest a good efficacy/safety profile.
Les premiers résultats fournis par un programme de phase III impliquant plus de 4 200 patients dans 30 pays indiquent un bon profil efficacité/innocuité.